Pettitt, A.R., Matutes, E. M. and Oscier, D. G., 2006. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, pp. 1441-1445.
Full text not available from this repository.
Official URL: http://www.nature.com/leu/journal/v20/n8/abs/24042...
A letter to the editor is presented in response to an article about the feasibility and efficacy of alemtuzumab combined with methylprednisolone as a therapeutic regimen in chronic lymphocytic leukemia patients with p53 defects.
|Subjects:||Technology > Medicine and Health|
|Group:||School of Health and Social Care > Centre for Postgraduate Medical Research and Education|
|Deposited By:||INVALID USER|
|Deposited On:||02 Nov 2008 15:56|
|Last Modified:||07 Mar 2013 14:51|
|Repository Staff Only -|
|BU Staff Only -|
|Help Guide -||Editing Your Items in BURO|